|1.||Win, T: 1 article (01/2005)|
|2.||Bittner, S: 1 article (01/2005)|
|3.||Gupta, R C: 1 article (01/2005)|
08/01/1988 - "These data suggest that TCNU may be useful in the management of large bowel cancer as the MAC system has been previously shown to be a good model of human disease."
01/01/1991 - "Compared to control animals, TCNU decreased tumor growth. "
05/01/1990 - "The variability in the tissue level of TCNU was partly attributable to variable absorption of the drug, since peak plasma TCNU levels ranged from 164 to 3333 ng/ml. There were close quantitative and temporal relationships between the times of peak plasma levels (median 456 ng/ml at 45 minutes after administration), peak tumor levels (median 250 ng/gm tissue at 55 minutes), and brain adjacent to tumor levels (median 256 ng/gm tissue at 50 minutes). "
05/01/1990 - "High-performance liquid chromatography analysis of 32 tumor specimens for TCNU revealed that tissue concentrations ranged from 0 to 554 ng/gm: TCNU was not detected in necrotic regions of the tumor. "
01/01/1989 - "Pharmacokinetics of tauromustine in cancer patients. "
07/01/1990 - "TCNU in adenocarcinoma of the lung: a phase II study with divided doses."
07/01/1990 - "Accordingly, 38 consecutive patients with non-resectable adenocarcinoma of the lung received TCNU 40 mg/m2 p.o. "
08/01/1988 - "TCNU is highly active against a panel of three histologically distinct transplantable murine adenocarcinomas of the colon (MAC tumours). "
08/01/1988 - "The novel nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosoure a (TCNU) is active against a panel of three transplantable murine adenocarcinomas of the colon of varying growth characteristics and morphology (MAC system). "
04/01/1990 - "Phase II trial of TCNU and vindesine in patients with adenocarcinoma of the lung."
01/01/1987 - "TCNU produced significantly greater cytotoxicity in the Mer- cells (Walker 256 rat breast carcinoma resistant to nitrogen mustards; human lung carcinoma A427) than in the Mer+ cells (Walker 256 wild-type; human lung carcinoma A594). "
01/01/1987 - "The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)ethyl]-1-nitrosour ea (TCNU) on cytotoxicity, DNA crosslinking and glutathione reductase in lung carcinoma cell lines."
05/01/1993 - "Degradable starch microspheres in cytostatic treatment of a liver carcinoma; experimental studies in rats with 5-fluorouracil, tauromustine, carmustine, doxorubicin and RSU-1069."
|4.||Colorectal Neoplasms (Colorectal Cancer)
07/01/1989 - "It is concluded that TCNU is a well tolerated compound with limited, but definite antitumor activity against colorectal cancer and that further studies in this disease could be of interest."
02/01/1996 - "TCNU in colorectal cancer. "
01/01/1993 - "In 25 patients with advanced colorectal carcinoma (13 M, 12 F, median age 51 yrs), four dose levels of TCNU (25, 30, 35 or 40 mg/m2) were investigated. "
07/01/1989 - "TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer. "
01/01/1990 - "5-Fluorouracil plus tauromustine in advanced colorectal cancer: unexpected negative results."
|5.||Melanoma (Melanoma, Malignant)
01/01/1994 - "Phase II study of tauromustine in disseminated malignant melanoma."
04/01/1989 - "Phase II study of tauromustine in disseminated malignant melanoma."
01/01/1993 - "Tauromustine was administered orally in weekly doses with interindividual dose escalation to patients with disseminated malignant melanoma. "
04/01/1989 - "It appears that TCNU is active in disseminated malignant melanoma with a response rate similar to other nitrosoureas."
04/01/1989 - "Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. "
|1.||1- (2- chloroethyl)- 3- (2- (dimethylaminosulfonyl)ethyl)- 1- nitrosourea (tauromustine)
|3.||degradable starch microspheres
|8.||Leucovorin (Folinic Acid)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)